| 词条 | Satralizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu/o | target = interleukin 6 receptor | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 1535963-91-7 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = 6340 | H = 9776 | N = 1684 | O = 2022 | S = 46 | molecular_weight = 143.4 g/mol | UNII = YB18NF020M | KEGG = D11079 | synonyms = SA237 }} Satralizumab (SA237, formerly sapelizumab) (INN[1]) is a monoclonal antibody that is being investigated for neuromyelitis optica spectrum disorder[2]. This drug is being developed by Chugai Pharma in conjunction with Roche. {{as of|2018}}, satralizumab is undergoing Phase III trials.[3] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for immune system}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab, American Medical Association. 3. ^[https://www.biospace.com/article/releases/chugai-presents-results-from-phase-iii-study-of-satralizumab-in-nmosd-at-ectrims-2018] 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。